Recon: J&J, BMS and AstraZeneca appeal IRA court losses; Swiss biotech Asceneuron raises $100M to develop Alzheimer’s drug
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States